Taysha Gene Therapies Inc expected to post a loss of $1.07 a share - Earnings Preview

Taysha Gene Therapies

13/05/2022 13:40

* Taysha Gene Therapies Inc  TSHA.OQ   TSHA.O  is expected
to show
no change in quarterly revenue when it reports  results on May
16. 
    * ​Refinitiv's mean analyst estimate for Taysha Gene
Therapies Inc
is for a loss of $1.07 per share. For the same quarter last
year, the company reported a loss of 87 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 16 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Taysha Gene
Therapies Inc is $27​, above​ its last closing price of $3.07.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -1.25       -1.25      -1.32     Missed  -5.2
 Sep. 30 2021  -1.11       -1.08      -1.35     Missed  -25.2
 Jun. 30 2021  -0.85       -0.84      -1.09     Missed  -29.8​
 Mar. 31 2021  -0.67       -0.56      -0.87     Missed  -54.6
 ​​Dec.        -0.42       -0.37      -1.04     Missed  -177.3
 31 2020                                                
 Sep. 30 2020  -0.17       -0.17      -1.28     Missed  -631.4
                                                        ​
 This summary was machine generated May 13 at 12:40 GMT.  All
figures in US dollars  unless otherwise stated